Why the study?
Does aspirin prevent venous thromboembolism and reduce complications in patients undergoing total joint arthroplasty compared to other anticoagulants?
Does aspirin prevent venous thromboembolism and reduce complications in patients undergoing total joint arthroplasty compared to other anticoagulants?
Aspirin is an effective, safe, and cost-effective option for VTE prophylaxis in patients undergoing total joint arthroplasty, offering additional benefits like reduced infection and stiffness.
Supports aspirin consideration for VTE prophylaxis in TJA; hypothesis-generating and leaves open need for randomized confirmation.
Aspirin is increasingly being used for venous thromboembolism (VTE) prophylaxis in patients undergoing total joint arthroplasty (TJA). It is considered a safer and more cost-effective alternative to other anticoagulants, with the added benefit of not requiring blood-level titration. Studies have shown that aspirin is effective in preventing VTE, with a lower risk of major bleeding and reduced mortality compared to other options. Additionally, aspirin provides indirect benefits such as a reduced risk of periprosthetic joint infections (PJIs), heterotopic ossification (HO), and joint stiffness, with no significant difference in aseptic loosening rates when compared to stronger anticoagulants.
No takes yet. Share an insight, caveat, or question.
Jarusriwanna et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: